GlassScriptPhysician profile
Stephanie Hawk
NPI 1588305544
$1,508.55
in general payments reported to CMS, 2019-2025
15 companies · $583 in 2025
The $583 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $288 · 2023: $261 · 2024: $376 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $218.03 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $167.18 | 2022-2023 | Mounjaro, Jardiance |
| Boston Scientific Corporation | $141.58 | 2025 | Watchman Flx |
| Abbott Laboratories | $127.52 | 2022-2023 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $124.36 | 2025 | Auvelity |
| Corcept Therapeutics | $123.41 | 2024-2025 | Korlym |
| Acadia Pharmaceuticals INC | $122.17 | 2025 | Daybue |
| Biohaven Pharmaceutical Holding Company LTD. | $119.95 | 2022 | |
| Amarin Pharma, INC. | $112.65 | 2025 | Vascepa |
| W. L. Gore & Associates, INC. | $91.98 | 2024 | Gore Viabahn Endoprosthesis With Heparin |
| Coloplast Corp | $40.35 | 2023 | Altis |
| Bayer Healthcare Pharmaceuticals INC. | $39.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.02 | 2023 | |
| Phathom Pharmaceuticals, INC. | $25.22 | 2024 | Voquezna |
| Abbvie INC. | $17.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Hawk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.